SCHEMBL24138658

SCHEMBL24138658

C[C@@]12CC3CC(C(=S)N[C@H]4CC[C@H](N)CC4)(C1)C[C@](c1ccccc1)(C3)C2

nearest known ligand 0.41

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ KDM1A O60341 3/20 0.41
▸ MAOB P27338 2/20 0.41
▸ MAOA P21397 1/20 0.36
▸ EPHX2 P34913 5/20 0.36
▸ GRIN2D O15399 2/20 0.34
▸ GRIN3B O60391 2/20 0.34
▸ GRIN1 Q05586 2/20 0.34
▸ GRIN2A Q12879 2/20 0.34
▸ GRIN2B Q13224 2/20 0.34
▸ GRIN2C Q14957 2/20 0.34
▸ GRIN3A Q8TCU5 2/20 0.34
▸ LMNA P02545 2/20 0.34
▸ SMYD3 Q9H7B4 2/20 0.34
▸ ALDH1A1 P00352 1/20 0.33
▸ HSD11B1 P28845 1/20 0.33
▸ NPC1 O15118 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24139443 1.00 KDM1A (0.41) KDM1AMAOBMAOAEPHX2GRIN2D
SCHEMBL24138664 1.00 KDM1A (0.41) KDM1AMAOBMAOAEPHX2GRIN2D
SCHEMBL24274013 1.00 KDM1A (0.41) KDM1AMAOBMAOAEPHX2GRIN2D
SCHEMBL24139442 1.00 KDM1A (0.41) KDM1AMAOBMAOAEPHX2GRIN2D
SCHEMBL29329959 0.89 EPHX2 (0.41) EPHX2LMNAALDH1A1HSD11B1NPC1
SCHEMBL24138688 0.89 GRIN2D (0.35) KDM1AMAOBEPHX2GRIN2DGRIN3B
SCHEMBL24139387 0.89 GRIN2D (0.35) KDM1AMAOBEPHX2GRIN2DGRIN3B
SCHEMBL24139343 0.88 KDM1A (0.42) KDM1AMAOAEPHX2GRIN2DGRIN3B
SCHEMBL23488841 0.87 KDM1A (0.41) KDM1AMAOBMAOAEPHX2LMNA
SCHEMBL23489327 0.87 KDM1A (0.41) KDM1AMAOBMAOAEPHX2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240238265-A1 ADAMANTANE AMIDES AND THIOAMIDES FOR THE TREATMENT OF EBOLAVIRUS INFECTION ARISAN THERAPEUTICS INC. (US) 2024-07-18 — — US disclosed
WO-2021262426-A9 ADAMANTANE AMIDES AND THIOAMIDES FOR THE TREATMENT OF EBOLAVIRUS INFECTION ARISAN THERAPEUTICS INC. (US) 2022-03-17 — — WO disclosed
WO-2021262426-A2 ADAMANTANE AMIDES AND THIOAMIDES FOR THE TREATMENT OF EBOLAVIRUS INFECTION ARISAN THERAPEUTICS INC. (US) 2021-12-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240238265-A1 ADAMANTANE AMIDES AND THIOAMIDES FOR THE TREATMENT OF EBOLAVIRUS INFECTION IFNAR1, NR4A3, NR0B2 KDM1A 2593/4885MAOB 3347/4885MAOA 4330/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback